Lie symmetry analysis, multiple exp-function method and conservation laws for the (2+1)-dimensional Boussinesq equation
Optical and Quantum Electronics · 12.02.2024 · 56 (4)
DOI: 10.1007/s11082-024-06339-1 ↗Kurz gefasst
Fachartikel in der Zeitschrift Optical and Quantum Electronics, online erschienen am 12.02.2024. Verfasst von S. O. Mbusi und 2 weiteren Autor:innen. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of South Africa.
Abstract (Originalsprache)
In this study, we take into account the (2 + 1)-dimensional Boussinesq equation, a nonlinear evolution partial differential equation that describes how gravity waves move across the surface of the ocean. The symmetry reductions and group invariant precise solutions are systematically determined using the Lie symmetry analysis. We derive the precise multiple wave solutions using the multiple exp-function method, and then, using the multiplier method, we give the conservation laws. The dynamics of complicated waves and their interplay are faithfully recreated by the findings.
Förderung
- University of South Africa
Zitieren
APA
Mbusi, S. O., Adem, A. R., & Muatjetjeja, B. (2024). Lie symmetry analysis, multiple exp-function method and conservation laws for the (2+1)-dimensional Boussinesq equation. Optical and Quantum Electronics, 56(4). https://doi.org/10.1007/s11082-024-06339-1
Vancouver
Mbusi SO, Adem AR, Muatjetjeja B. Lie symmetry analysis, multiple exp-function method and conservation laws for the (2+1)-dimensional Boussinesq equation. Optical and Quantum Electronics. 2024;56(4). doi:10.1007/s11082-024-06339-1
BibTeX
@article{Mbusi2024,
author = {Mbusi, S. O. and Adem, A. R. and Muatjetjeja, B.},
title = {Lie symmetry analysis, multiple exp-function method and conservation laws for the (2+1)-dimensional Boussinesq equation},
journal = {Optical and Quantum Electronics},
year = {2024},
volume = {56},
number = {4},
doi = {10.1007/s11082-024-06339-1}
}
EUVIMED